FKBP5 and metabolic disease: SAFit2, a sulfonamide analog with FKBP5-binding properties, has emerged as a promising therapeutic target for stress-related psychiatric disorders and metabolic diseases and acts as a potent and highly selective FKBP5 inhibitor58.